Lung Cancer

Web Exclusives | April 2, 2021
To ensure optimal treatment selection and outcomes, differentiating between COVID-19 infection and interstitial lung disease is critical.
Web Exclusives | April 2, 2021
Efficacy of osimertinib as adjuvant therapy was demonstrated in ADAURA, a randomized, double-blind, placebo-controlled trial.
Web Exclusives | April 2, 2021
Positive findings from this study support channeling additional resources into telemedicine care for lung cancer, and into future randomized controlled trials to verify effectiveness.
Web Exclusives | April 2, 2021
The COVID-19 pandemic has highlighted how critical it is to maintain resilience and flexibility of the healthcare system and healthcare providers.
Web Exclusives | April 2, 2021
Clinical data are highlighted, providing an understanding of the benefits of treatment with tyrosine kinase inhibitors.
Over the past year, the COVID-19 pandemic has ushered in unprecedented changes in the practice of medicine and dissemination of treatment advances presented in scientific forums.
Osimertinib shows promise as an adjuvant treatment for patients with stage IB to IIIA EGFR mutation–positive NSCLC.
The open-label, phase 2 VISION study evaluated the efficacy and safety of tepotinib, a highly selective oral MET inhibitor, in patients with advanced NSCLC with MET alterations.
Patients treated with afatinib for EGFR-mutated (EGFRm) non–small-cell lung cancer (NSCLC) often require treatment modifications because of drug toxicities. This study aimed to evaluate the safety and efficacy of a lower dosage of afatinib in patients with EGFRm NSCLC.
Study results show no increase in progression-free survival with combination treatment of osimertinib and bevacizumab compared with osimertinib alone for patients with advanced lung adenocarcinoma and an EGFR T790M mutation.
Page 1 of 11
Results 1 - 10 of 102

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country
  • Please enter your mailing address.

    Address
     
    Address Line 2
    City
     
    State
    Zip Code